Medibank Private Limited (MPL.AX) stock analysis

In our weekly check, Medibank Private Limited is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2.

About Medibank Private Limited

Medibank Private Limited is a Financial Services company (Insurance - Life) based in Australia, listed on ASX as MPL.AX.

What our checks show for MPL.AX

Red flags

• The gross margin fell by 83 points, to 17.2%: costs are rising faster than prices.
• The dividend takes 113% of profit: little cushion if profit falls.

Warning signs

• Analysts expect only about 4.3% a year of growth in revenue.
• The net margin is only 6.8%: little room if costs rise.
• Recovering from its deepest fall took about 1.9 years.

Strengths

• The net margin rose by 1.3 points over 5 years, to 6.8%.
• Beta 0.05: the stock usually moves less than the market.
• Actively traded: about 7 million shares a day.
• Return on capital (ROCE) is 19.5%: the business earns well on the money put into it.
• Pay in shares is only 0% of free cash flow.

Similar companies

GL · 8210.SR · SDLF.L · JXN · VOYA

Questions

What grade does Medibank Private Limited (MPL.AX) have?

In our weekly check, Medibank Private Limited is graded B (A to F). Of 25 checks on debt, profit, cash flow and trend: 20 pass, warnings: 3, red flags: 2. The grade is a risk check, not a buy or sell recommendation.

What are the main risks of MPL.AX stock?

This week's biggest flags for Medibank Private Limited: Gross margin falling, Dividend stretched, Weak revenue forecast. In total 5 of 25 checks show a warning or a red flag.

What does Medibank Private Limited do?

Medibank Private Limited is a Financial Services company (Insurance - Life) based in Australia, listed on ASX as MPL.AX.

The grade is a risk check, not a price forecast, and not investment advice. In our 10-year test (S&P 500, 2016-2026), stocks we graded A or B fell more than 30% 2-3 times less often than D or F, without a lower average return.

Updated 2026-10-31

Open the full analysis